Maraviroc: A Coreceptor CCR5 Antagonist for Management of HIV Infection

Raymond Yost; Timothy R. Pasquale; Eric G. Sahloff

Disclosures

Am J Health Syst Pharm. 2009;66(8):715-726. 

In This Article

Conclusion

Available data support the use of maraviroc, the first CCR5 antagonist to receive FDA marketing approval, as part of an optimized antiretroviral regimen in treatment-experienced patients infected with CCR5-tropic HIV.

After this manuscript was accepted for publication, a more sensitive tropism test was developed and validated. This tropism assay replaces the previous assay and is still commercially available under the name Trofile. The enhanced assay is 100% sensitive in detecting 0.3% CXCR4-tropic minor variants.[52] As previously noted, the Trofile tropism assay requires a viral load of > 1000 copies/mL and should be performed before the initiation of maraviroc.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....